Daraprim
(Pyrimethamine)ApprovedSmall molecule
Pyrimethamine is used to treat malaria and certain parasitic infections like toxoplasmosis. It works by stopping parasites from growing and multiplying in the body.[2] Daraprim is currently approved and in use across 14 indications[4].[1]
Daraprim is one of 341 small molecule programs targeting Toxoplasmosis. It is currently in Approved.
14
Indications
25
Total Trials
2
Active Trials
340
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
123 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Norvir
AbbVieApproved
Daraprim
FFondazione Matilde Tettamanti Menotti De Marchi Onlus
Approved
Olumiant
Eli LillyApproved
Arava
SanofiApproved
Reyataz
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Niacor
AbbVieApproved
Soriatane
GSKApproved
Rifadin
SanofiApproved
Ninlaro
TakedaApproved
Tybost
GileadApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Encephalitis4 trials
Show 1 more trial
HIV2 trials
Myelodysplastic Syndromes1 trial
Familial Amyotrophic Lateral Sclerosis1 trial
15 more indications
Head and Neck Squamous Cell Carcinoma1 trial
Sandhoff disease1 trial
Schizophrenia1 trial
Azithromycin1 trial
Drug1 trial
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Completed·—·Phase 1/2·NCT01066663·20 enrolled
Vaccination1 trial
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03952650·252 enrolled
Lymphoproliferative Syndrome1 trial
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00065390·8 enrolled
Cerebral Toxoplasmosis1 trial
Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000643·150 enrolled
Treatment1 trial
A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000973·26 enrolled
Pneumonia1 trial
A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000727·322 enrolled
Congenital Toxoplasmosis1 trial
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00004317·600 enrolled
Prophylaxis1 trial
Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02511054·57 enrolled
Unspecified2 trials
Dose Escalation PfSPZ-CVac
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03083847·55 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
DARAPRIM
NDA NDA008578
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Daraprim drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pyrimethamine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details